BACKGROUND: Previous reports suggest that intact SMAD4 expression is associated with a locally aggressive pancreas cancer phenotype. The objectives of this work were to determine the frequency of intact SMAD4 and its association with patterns of recurrence in patients with upfront resected pancreas cancer receiving adjuvant therapy. METHODS: A tissue microarray was constructed using resected specimens from patients who underwent upfront surgery and adjuvant gemcitabine with no neoadjuvant treatment for pancreas cancer. SMAD4 expression was determined by immunohistochemical staining. Associations of SMAD4 expression and clinicopathologic parameters with clinical outcomes were evaluated using Cox proportional hazard models. RESULTS: One hundred twenty-seven patients were included with a median follow up of 5.7 years. Most patients had stage ≥ pT3 tumors (75%) and pN1 (68%). All patients received adjuvant gemcitabine, and 79% of patients received adjuvant chemoradiotherapy. Ten (8%) patients had intact SMAD4 expression. Grade was the only clinicopathologic parameter statistically associated with SMAD4 expression (P=0.05). Median overall survival was 2.1 years. On univariate analysis, SMAD4 expression was associated with increased locoregional recurrence (hazard ratio 7.0, P<0.01, 95% confidence interval: 2.8-18.0) but not distant recurrence (P=0.06) or overall survival (P=0.73). On multivariable analysis, SMAD4 expression (hazard ratio 9.6, P<0.01, 95% confidence interval: 3.7-24.8) and adjuvant chemoradiotherapy (hazard ratio 0.3, P=0.01, 95% confidence interval: 0.1-0.8) were associated with higher and lower locoregional recurrence, respectively. CONCLUSIONS: In patients with upfront resected pancreas cancer, SMAD4 expression was associated with an increased risk of locoregional recurrence. Prospective evaluation of the frequency of SMAD4 expression and validation of its predictive utility is warranted. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Previous reports suggest that intact SMAD4 expression is associated with a locally aggressive pancreas cancer phenotype. The objectives of this work were to determine the frequency of intact SMAD4 and its association with patterns of recurrence in patients with upfront resected pancreas cancer receiving adjuvant therapy. METHODS: A tissue microarray was constructed using resected specimens from patients who underwent upfront surgery and adjuvant gemcitabine with no neoadjuvant treatment for pancreas cancer. SMAD4 expression was determined by immunohistochemical staining. Associations of SMAD4 expression and clinicopathologic parameters with clinical outcomes were evaluated using Cox proportional hazard models. RESULTS: One hundred twenty-seven patients were included with a median follow up of 5.7 years. Most patients had stage ≥ pT3 tumors (75%) and pN1 (68%). All patients received adjuvant gemcitabine, and 79% of patients received adjuvant chemoradiotherapy. Ten (8%) patients had intact SMAD4 expression. Grade was the only clinicopathologic parameter statistically associated with SMAD4 expression (P=0.05). Median overall survival was 2.1 years. On univariate analysis, SMAD4 expression was associated with increased locoregional recurrence (hazard ratio 7.0, P<0.01, 95% confidence interval: 2.8-18.0) but not distant recurrence (P=0.06) or overall survival (P=0.73). On multivariable analysis, SMAD4 expression (hazard ratio 9.6, P<0.01, 95% confidence interval: 3.7-24.8) and adjuvant chemoradiotherapy (hazard ratio 0.3, P=0.01, 95% confidence interval: 0.1-0.8) were associated with higher and lower locoregional recurrence, respectively. CONCLUSIONS: In patients with upfront resected pancreas cancer, SMAD4 expression was associated with an increased risk of locoregional recurrence. Prospective evaluation of the frequency of SMAD4 expression and validation of its predictive utility is warranted. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Pancreas cancer; chemoradiotherapy (CRT); mothers against decapentaplegic homolog 4 (SMAD4); patterns of recurrence; tissue microarray (TMA)
Authors: M Tascilar; H G Skinner; C Rosty; T Sohn; R E Wilentz; G J Offerhaus; V Adsay; R A Abrams; J L Cameron; S E Kern; C J Yeo; R H Hruban; M Goggins Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: J B Bachet; R Maréchal; P Demetter; F Bonnetain; A Couvelard; M Svrcek; A Bardier-Dupas; P Hammel; A Sauvanet; C Louvet; F Paye; P Rougier; C Penna; J C Vaillant; T André; J Closset; I Salmon; J F Emile; J L Van Laethem Journal: Ann Oncol Date: 2012-02-29 Impact factor: 32.976
Authors: Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban Journal: CA Cancer J Clin Date: 2013-07-15 Impact factor: 508.702
Authors: Nicholas J Roberts; Alexis L Norris; Gloria M Petersen; Melissa L Bondy; Randall Brand; Steven Gallinger; Robert C Kurtz; Sara H Olson; Anil K Rustgi; Ann G Schwartz; Elena Stoffel; Sapna Syngal; George Zogopoulos; Syed Z Ali; Jennifer Axilbund; Kari G Chaffee; Yun-Ching Chen; Michele L Cote; Erica J Childs; Christopher Douville; Fernando S Goes; Joseph M Herman; Christine Iacobuzio-Donahue; Melissa Kramer; Alvin Makohon-Moore; Richard W McCombie; K Wyatt McMahon; Noushin Niknafs; Jennifer Parla; Mehdi Pirooznia; James B Potash; Andrew D Rhim; Alyssa L Smith; Yuxuan Wang; Christopher L Wolfgang; Laura D Wood; Peter P Zandi; Michael Goggins; Rachel Karchin; James R Eshleman; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Ralph H Hruban; Alison P Klein Journal: Cancer Discov Date: 2015-12-09 Impact factor: 39.397
Authors: Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook Journal: JAMA Surg Date: 2016-08-17 Impact factor: 14.766